Proton Pump Inhibitors and Cyclin-Dependent Kinase 4/6 Inhibitors in Patients With Breast Cancer

被引：4

作者：

Takahashi, Kaori ^{[1
]}

Uozumi, Ryuji ^{[2
]}

Mukohara, Toru ^{[3
]}

Hayashida, Tetsu ^{[4
]}

Iwabe, Midori ^{[5
]}

Iihara, Hirotoshi ^{[6
]}

Kusuhara-Mamishin, Kanako ^{[7
]}

Kitagawa, Yuko ^{[4
]}

Tsuchiya, Masami ^{[5
]}

Kitahora, Mika ^{[6
]}

Nagayama, Aiko ^{[4
]}

Kosaka, Shinkichi ^{[8
]}

Asano-Niwa, Yoshimi ^{[9
]}

Seki, Tomoko ^{[4
]}

Ohnuki, Koji ^{[10
]}

Suzuki, Akio ^{[6
]}

Ono, Fumiko ^{[4
]}

Futamura, Manabu ^{[9
]}

Kawazoe, Hitoshi ^{[1
,11
,12
]}

Nakamura, Tomonori ^{[1
,11
]}

机构：

[1] Keio Univ, Fac Pharm, Ctr Social Pharm & Pharmaceut Care Sci, Div Pharmaceut Care Sci, Tokyo, Japan

[2] Tokyo Inst Technol, Dept Ind Engn & Econ, Tokyo, Japan

[3] Natl Canc Ctr Hosp East, Dept Med Oncol, Chiba, Japan

[4] Keio Univ, Sch Med, Dept Surg, Tokyo, Japan

[5] Miyagi Canc Ctr, Dept Pharm, Natori, Miyagi, Japan

[6] Gifu Univ Hosp, Dept Pharm, Gifu, Japan

[7] Natl Canc Ctr Hosp East, Dept Pharm, Chiba, Japan

[8] Natl Hosp Org Mito Med Ctr, Dept Surg, Ibaraki, Japan

[9] Gifu Univ Hosp, Dept Breast Surg, Gifu, Japan

[10] Miyagi Canc Ctr, Dept Breast Surg, Natori, Miyagi, Japan

[11] Keio Univ, Grad Sch Pharmaceut Sci, Div Pharmaceut Care Sci, Tokyo, Japan

[12] Keio Univ, Grad Sch Pharmaceut Sci, Div Pharmaceut Care Sci, 1-5-30 Shibakoen,Minato Ku, Tokyo 1058512, Japan

来源：

ONCOLOGIST | 2024年 / 29卷 / 06期

关键词：

breast cancer; palbociclib; abemaciclib; proton pump inhibitor; propensity score; PROPENSITY SCORE; PALBOCICLIB; PHARMACOKINETICS; THERAPY; AGENTS;

D O I：

10.1093/oncolo/oyae015

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Background Proton pump inhibitors (PPIs) reduce the bioavailability of several anticancer drugs. The impact of PPIs co-administered with cyclin-dependent kinase 4 and 6 inhibitors is controversial. We aimed to clarify whether the concomitant use of PPIs impacts palbociclib and abemaciclib effectiveness in breast cancer treatment.Patients and Methods This multicenter, retrospective, observational study, conducted across 4 medical institutions in Japan, consecutively included patients with endocrine-resistant metastatic breast cancer, receiving palbociclib or abemaciclib between December 2017 and August 2022. Propensity score-matched analyses were performed. Treatment efficacy and safety with and without PPIs were compared. Progression-free survival and overall survival were estimated using the Kaplan-Meier method and compared using a log-rank test. A Cox proportional hazards model was used to estimate the hazard ratio.Results The study included 240 patients. After 1:1 matching, 112 patients were treated with and without PPIs. The median progression-free survival period was 1.2 years in the PPI group and 1.3 years in the non-PPI group (hazard ratio, 1.19; 95% CI, 0.70-2.02). The median overall survival period was 3.6 years in the PPI group, whereas it was not reached in the non-PPI group (hazard ratio, 1.23; 95% CI, 0.61-2.47). Consistent results were obtained for subgroups receiving palbociclib (n = 177) and abemaciclib (n = 63) without propensity score matching. Adverse event incidence and severity were similar in both groups.Conclusion The effectiveness of cyclin-dependent kinase 4/6 inhibitors is unlikely to be affected by concomitant PPI use. Future prospective pharmacokinetic studies are warranted. The impact of the co-administration of proton pump inhibitors with cyclin-dependent kinase 4 and 6 inhibitors remains controversial. This study clarified whether the concomitant use of proton pump inhibitors impacts the effectiveness of palbociclib and abemaciclib in patients with breast cancer.

引用

页码：e741 / e749

页数：9

共 50 条

[31] The Use of Cyclin-Dependent Kinase 4/6 Inhibitors in Elderly Breast Cancer Patients: What Do We Know?
Sorscher, Steven
CANCERS, 2024, 16 (16)
[32] Cyclin-dependent kinase inhibitors
Westwell, A
DRUG DISCOVERY TODAY, 2001, 6 (09) : 491 - 491
[33] Cyclin-dependent kinase inhibitors
Dai, Y
Grant, S
CURRENT OPINION IN PHARMACOLOGY, 2003, 3 (04) : 362 - 370
[34] Venous thromboembolism in breast cancer patients receiving cyclin-dependent kinase inhibitors.
Gervaso, Lorenzo
Montero, Alberto J.
Jia, Xuefei
Khorana, Alok A.
JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
[35] Combination of Cyclin-Dependent Kinase 4 Inhibitors and Androgen Receptor Inhibitors as Cancer Therapy
Abdel-Magid, Ahmed F.
ACS MEDICINAL CHEMISTRY LETTERS, 2022, 13 (09): : 1408 - 1410
[36] Do proton pump inhibitors affect the effectiveness of cyclin-dependent kinase 4/6 inhibitors in advanced HR positive, HER2 negative breast cancer? A meta-analysis
de Moraes, Francisco Cezar Aquino
Pereira, Caroline R. M.
Sano, Vitor Kendi Tsuchiya
Laia, Estella Aparecida De
Stecca, Carlos
Burbano, Rommel Mario Rodriguez
FRONTIERS IN PHARMACOLOGY, 2024, 15
[37] Cyclin-dependent kinase 4/6 inhibitors in the treatment of advanced oestrogen receptor-positive breast cancer
Dubianski, Roman
Jagiello-Gruszfeld, Agnieszka
Nowecki, Zbigniew
ONCOLOGY IN CLINICAL PRACTICE, 2016, 12 (06): : 209 - 214
[38] Emerging Skin Toxicities in Patients with Breast Cancer Treated with New Cyclin-Dependent Kinase 4/6 Inhibitors: A Systematic Review
Silvestri, Martina
Cristaudo, Antonio
Morrone, Aldo
Messina, Claudia
Bennardo, Luigi
Nistico, Steven Paul
Mariano, Maria
Cameli, Norma
DRUG SAFETY, 2021, 44 (07) : 725 - 732
[39] Timing of Dose Reductions and Survival Outcomes in Metastatic Breast Cancer Patients Treated with Cyclin-Dependent Kinase 4/6 Inhibitors
Kubilay Tolunay, Pinar
Kurt Inci, Bediz
Usta, Sura
Topkac, Ali
Karabuga, Berkan
Aydemir, Ergin
Oner, Irem
Akay Hacan, Busra
Ates, Ozturk
Karacin, Cengiz
Yalcintas Arslan, Ulku
CURRENT ONCOLOGY, 2024, 31 (12) : 7426 - 7436
[40] A meta-analysis and systematic review of different cyclin-dependent kinase 4/6 inhibitors in breast cancer
Zhang, Jialin
Xu, Xinyu
Zhou, Yeyue
Su, Jingyang
Wang, Jue
FRONTIERS IN ONCOLOGY, 2025, 15

← 1 2 3 4 5 →